White adipose tissue (WAT) is now recognised as an endocrine organ through its secretion of hormones and protein factors - ‘adipokines’.  This thesis examined the regulation of two adipose expressed genes, retinol binding agent (RBP) involved in retinol transport, and tissue factor (TF) which initiates the extrinsic coagulation cascade.  RNA was isolated and RBP and mRNA levels determined by chemiluminescence-based Northern blotting.  TF and mRNA levels were determined by real-time PCR.  WAT RBP mRNA levels were second only to liver, and TF mRNA levels were highest in WAT depots.  RBP and TF mRNA were detected predominantly from mature adipocytes.  Obesity was not associated with altered RBP and TF gene expression except of for a significant (<i>p</i><0.05) decrease in RBP mRNA from subcutaneous WAT of obese rodent models.  Primary adipocytes were treated with <span lang=EN-GB style='font-family:Symbol'>b-agonists, dexamethasone or leptin.  Only dexamethasone significantly (<i>p</i><0.05) reduced RBP mRNA levels.  TF mRNA levels were unaltered following <span lang=EN-GB style='font-family:Symbol'>b-agonists, forskolin, or dexamethasone treatment except for a significant (<i>p</i><0.05) increase with a high dose of BRL 37344 (a <span lang=EN-GB style='font-family:Symbol'>b₃ agonist).  Administration of two isoforms of retinoic acid significantly decreased RBP gene expression, with 9-<i>cis</i> showing more potency (<i>p</i><span lang=EN-GB style='font-family:Symbol'>£ 0.001) that all-<i>trans</i> (<i>p</i><0.05.  The thiazolidinediones ciglitazone and rosiglitazone were administered, high doses significantly reducing RBP gene expression (<i>p</i> <span lang=EN-GB style='font-family:Symbol'>£ 0.001 and <i>p </i><span lang=EN-GB style='font-family:Symbol'>£ 0.05 respectively).  Fasting and cold exposure are two physiological stimuli which stimulate substrate flux and the release of fatty acids from WAT.  RBP gene expression in WAT was unaltered with fasting, cold exposure and <span lang=EN-GB style='font-family:Symbol'>b-agonist injection.  These studies suggest WAT may be an important source of RBP and TF.  In contrast to lipolysis and leptin production, the SNS does not significantly regulate RBP and TF gene expression.  The high TF gene expression in rodent WAT suggests an association between TF and the cardiovascular disease seen with obesity.

Philosophiae Doctor - PhD / Obesity is a complex metabolic disease of excessive fat accumulation. It is a worldwide epidemic affecting billions of people and its pharmacological management is hampered by drug toxicity and undesirable side effects. Therefore, a need still exists for the development of safe medication for treatment of obesity. Nanotechnology involves the use of small particles at atomic and molecular scale. It has application in medical diagnostics, drug delivery and molecular imaging. Various nanoparticles (NPs) functionalized with different biomolecules have been successfully used in many therapeutic and research applications due to their versatility, ease of chemical synthesis, low toxicity and unique properties. Examples of NPs used in this study are Gold nanoparticles (GNPs) and Quantum dots (QDs). GNPs and QDs are extensively used as drug delivery, labelling and imaging tools in biomedical research. Nanotechnology offers a new potential useful avenue for solving the problem of toxicity of anti-obesity drugs. This could be achieved through targeted drug delivery. In this study, rats were fed a high fed diet (HFD) to induce obesity. The streptavidin conjugated GNPs and QDs were functionalized with biotinylated adipose-homingpeptide (AHP) and/or anti-obesity drug (Gallic acid). Functionalization was characterized using agarose gel electrophoresis, UV-vis spectroscopy and transmission electron microscopy. The binding-specificity and targeting ability of AHP was evaluated in vitro and in vivo. The apoptotic effect of AHP functionalized-drug loaded GNPs (AHP-GA-GNPs) was tested in vitro using APOPercentage TM and Caspase-3 activation assays. The in vitro data indicated that the binding was specific to prohibitin (PHB) expressing cells (MCF-7 and Caco-2), and that the binding was temperature dependent. PHB was confirmed as a target for AHP after overlaying AHP-FITC and anti-prohibitin antibody staining. Cellular uptake was detected on the cells treated with AHP-functionalized NPs as compared to unfunctionalized NPs. The GA and AHP-GA-GNPs reduced cellular viability and induced apoptosis through activation of Caspase-3. The Ex-vivo studies using primary endothelial cells (ECs) isolated from the WAT of lean and obese Wistar rats showed that the binding of AHP was receptor mediated, and specific to receptors differentially expressed in ECs from obese WAT. The in vivo studies showed that, treatment of obese rats with AHP-functionalized NPs resulted in targeted delivery of the NPs to the WAT as compared to those treated with unfunctionalized NPs. Qualitative analysis using fluorescence microscopy and IVIS Luminar XR, live-imaging system showed that the unfunctionalized NPs accumulated mostly in the organs of the reticuloendothelial system, namely: liver, spleen, lungs and kidneys. In contrast, AHP-functionalized NPs accumulated mostly in the WATs as compared to the rest of the organs of the obese rats. Uptake and binding of the NPs to the tissues was quantitatively confirmed by the inductive coupled plasma-optical emission spectroscopy (ICP-OES). In conclusion, this study reports the 1) successful functionalization of GNPs and QDs with AHP, 2) use of AHP-functionalized GNPs and QDs as delivery and imaging agents to the WAT, and 3) potential use of AHP-functionalized drug-loaded GNPs in the treatment of obesity.

京都大学 / 0048 / 新制・課程博士 / 博士(人間・環境学) / 甲第21862号 / 人博第891号 / 新制||人||213(附属図書館) / 2018||人博||891(吉田南総合図書館) / 京都大学大学院人間・環境学研究科共生人間学専攻 / (主査)教授 林 達也, 教授 石原 昭彦, 教授 久代 恵介 / 学位規則第4条第1項該当 / Doctor of Human and Environmental Studies / Kyoto University / DGAM

No description available.

No description available.

Obesity is a disease characterized by chronic inflammation and the progressive loss in systemic insulin sensitivity. One of the more effective medications in the treatment of insulin resistance have been the thiazolidinediones (TZDs), which act through the nuclear receptor peroxisome proliferator-activated receptor gamma (PPARgamma ). Due to the many side-effects of TZDs, our laboratory sought out a natural phytochemical, abscisic acid (ABA), with chemical similarities to TZDs. Our first study demonstrated that ABA activates PPARgamma in vitro and significantly ameliorates white adipose tissue (WAT) inflammation and glucose tolerance in db/db mice. We next further examined the effect of ABA on the phenotype of adipose tissue macrophages (ATMs). In doing so, we discovered two separate ATM populations which differed in their expression of the macrophage surface glycoprotein and maturation marker F4/80 (F4/80hi vs F4/80lo). Dietary ABA-supplementation significantly reduced F4/80hiCCR2+ ATMs and had no effect on the F4/80lo population. Utilizing a tissue-specific knockout generated through Cre-lox recombination, we were able to determine that this effect was dependent on PPARgamma in immune cells. To further characterize the differences between the ATM subsets that were affected by ABA, we performed a multi-organ assessment (i.e., WAT, skeletal muscle and liver) of the effect of diet-induced obesity on the phenotype of infiltrating macrophages and T cells into metabolic organs. Based on our new data, we formulated a model by which F4/80hiCCR2hi ATMs infiltrate WAT and ultimately induce a CD11c+ pro-inflammatory phenotype in the resident F4/80loCCR2lo subset. Ultimately, our findings provide evidence that ABA has potential as an alternative preventive intervention, expound the role of PPARgamma in immune cells and, in general, expand our knowledge concerning the immunopathogenesis of obesity-induced insulin resistance. / Ph. D.

A hiperglicemia crônica no diabetes está relacionada com distúrbios nas vias de sinalização da insulina e do mTOR, e com o desbalanço na secreção de adipocinas pelo tecido adiposo branco (TAB). Em longo prazo, esta disfunção metabólica pode causar uma perda severa de massa adiposa, o que agrava a resistência à insulina (RI). Estudos têm destacado o potencial efeito da suplementação com leucina no tratamento de doenças metabólicas como o diabetes tipo 2 e obesidade. No entanto, os efeitos da leucina sobre a homeostase glicêmica e a sensibilidade à insulina em doenças em que ocorre perda severa de gordura ainda necessitam melhores esclarecimentos. Portanto, foi investigado se a suplementação crônica com leucina pode afetar a adiposidade de ratos diabéticos com perda intensa de TAB, e melhorar a RI e outras desordens metabólicas relacionadas com TAB. Ratos recém-desmamados foram distribuídos em 3 grupos: i) Grupo controle (C) - não diabético e recebiam ração controle; ii) Grupo diabetes (D) - diabético e recebiam ração controle; iii) Grupo diabetes Leucina (DL) - diabético e recebiam ração suplementada com 5% de L-leucina. Após 8 semanas, foram analisados: glicemia e insulinemia de jejum, HOMAIR, citocinas pro- e anti-inflamatórias no soro e tecido adiposo branco, expressão de proteínas (mTOR, p-MTOR, p70S6K1, p-p70S6K1, PPAR&#947, C/EBP&#945;, ACC1, FAS, AKT, p-AKT) nos tecidos adiposos subcutâneo (SC) e retroperitoneal (RP), bem como a expressão de RNAm da adiponectina e leptina no TAB. In vivo, foram realizados testes de tolerância oral à glicose (OGTT) e de sensibilidade à insulina (ITT), glicemia pós prandial e consumo de ração. O tratamento crônico com leucina reverteu a perda de massa adiposa dos coxins subcutâneo e viscerais neste modelo experimental, o que pode ser explicado pelo aumento da expressão da p-p70S6K1, PPAR&#947;, ACC1 e FAS, proteínas que estimulam a adipogênese e lipogênese de novo nos adipócitos. Além disso, houve um aumento da expressão de AKT total no coxim SC no grupo DL, mas não foi alterada no coxim RP, indicando que a leucina também pode melhorar a resistência à insulina por ativar a AKT, que é considerada enzima limitante da cascata de fosforilação da insulina. Por outro lado, a leucina melhorou o perfil de adipocinas secretadas pelo coxim RP, pois aumentou a secreção de adiponectina e IL-10. Estas citocinas, direta ou indiretamente, reduzem a RI em tecidos como fígado, TAB e músculo esquelético. Isto sugere que a ação da leucina sobre a sensibilidade à insulina no coxim subcutâneo parece estar mais relacionada com a recuperação da via de sinalização da insulina, ao passo que, no coxim RP está indiretamente relacionada com a melhora do perfil de adipocinas secretadas por este tecido. Estes dados corroboram com os resultados de HOMAIR, glicemia de jejum e pós prandial, OGTT e ITT, nos quais foi observada uma significativa melhora do quadro de intolerância à glicose e resistência à insulina em ratos diabéticos tratados com leucina. Em conclusão, a suplementação crônica com leucina aumentou a adiposidade corporal em ratos diabéticos induzido por estreptozotocina no período neonatal, o que foi relacionado com a melhora da intolerância à glicose e da resistência à insulina. Isto demonstra que a recuperação trófica do tecido adiposo branco é fundamental para a melhora dos distúrbios metabólicos relacionados ao metabolismo da glicose neste modelo experimental. / The chronic hyperglycemia in diabetes is associated with disturbances in insulin and in mTOR pathways, and changes in adipokine secretion in white adipose tissue (WAT). Long-term, this metabolic dysfunction can cause a severe loss of fat mass, which increases insulin resistance (IR). Studies have highlighted the effect of leucine supplementation in treatment of metabolic diseases as type 2 diabetes and obesity. However, the effects of leucine on glucose homeostasis and insulin sensitivity in diseases with intense fat loss remain unknown. Therefore, was investigated whether chronic leucine supplementation can affect the adiposity of diabetic rats with severe adipose tissue loss, and to improve the IR and other metabolic disorders associated with WAT. After weaning, rats were distributed in 3 groups: i) control group (C) - no diabetic and received control chow ; ii) diabetes group (D) - diabetic and received control chow; iii) Leucine Diabetes Group (DL) - diabetic and received diet supplemented with 5% L-leucine. After 8 weeks, were analyzed: fasting glycaemia and insulin, HOMA>IR, antiinflammatory and proinflammatory cytokines in serum and in WAT, protein expression of mTOR, p-MTOR, p70S6K1, p-p70S6K1, PPAR&#947;, C/EBP&#945;, ACC1, FAS, AKT, p-AKT in subcutaneous (SC) and retroperitoneal adipose tissue, as well as the RNAm expression of adiponectin and leptin in WAT. In vivo, were realized oral glucose tolerance test (OGTT) and insulin sensitivity test (ITT), postprandial glycaemia and chow ingestion. O chronic treatment with leucine recovered the adipose mass in subcutaneous and visceral fat pad in this experimental model, this was explicated by increase of protein expression of p-p70S6K1, PPAR&#947;, ACC1 and FAS that stimulate the adipogenesis and de novo lipogenesis in adipocytes. Moreover, had an increase of protein expression of total AkT in subcutaneous fat pad in group DL, but don\'t change in RP fat pad, indicating that the leucine can to activate the AKT, which is limiting enzyme of phosphorylation cascade of insulin, and improve the insulin resistance. On the other hand, leucine improved the profile of adipokines secreted in RP fat pad, because increased the secretion of adiponectin and IL-10. This cytokines reduced the insulin resistance in tissues as liver, WAT and skeletal muscle. This suggest that action of leucine on insulin sensitivity in subcutaneous fat pad is more related to recovery of insulin signaling, and in RP fat pad is indirectly related to improve of profile of adipokines secretion in this tissue. This data corroborates with results of HOMAIR, postprandial and fasting glycaemia, OGTT and ITT, which showed significant improve of glucose intolerance and insulin resistance in diabetic rats treated with leucine. In conclusion, the chronic leucine supplementation increased adiposity in streptozotocin-induced diabetic rats in neonatal period, which was related to improve of glucose intolerance and insulin resistance. This show that trophic recovery of white adipose tissue is important for improve of metabolic disturbances related to glucose metabolism in this experimental model.

Embora seja na obesidade onde se observa hipertrofia e hiperplasia dos adipócitos e aumento da síntese e liberação de adipocinas, condição associada com resistência à insulina e disfunção endotelial, é de suma importância entender os efeitos biológicos de adipocinas, mais especificamente da adipocina chemerin, em condições não patológicas. Os mecanismos pelos quais as citocinas liberadas pelo tecido adiposo podem interferir na função vascular ainda não estão totalmente esclarecidos. Além disso, praticamente não se conhecem os efeitos da citocina/adipocina chemerin sobre a função vascular. Levando-se em consideração que o receptor para chemerin está presente no músculo liso vascular e no endotélio, este trabalho avaliou a atividade biológica e celular desta adipocina sobre a vasculatura de animais não obesos. Investigou-se os efeitos produzidos por esta citocina na reatividade vascular, bem como os mecanismos pelos quais ela modifica a função vascular em animais não obesos. A hipótese deste trabalho é que chemerin aumenta a reatividade vascular a estímulos constritores de endotelina-1 (ET-1) e fenilefrina (PhE) e diminui a vasodilatação induzida pela acetilcolina (ACh) e nitroprussitao de sódio (NPS). Nossos objetivos específicos incluíram determinar: 1) se chemerin promove alterações na reatividade vascular; 2) se as alterações de reatividade vascular promovidas por chemerin são mediadas por modificações da função das células endoteliais ou células de músculo liso vascular; 3) quais vias de sinalização (foco na via das MAPKs) estão sendo modificadas por chemerin e como elas contribuem para as alterações de reatividade vascular produzidas por esta citocina. Nosso estudo demonstrou que a adipocina chemerin possui atividade biológica e celular em aortas de ratos não obesos. Chemerin aumentou respostas vasculares a estímulos contráteis (ET-1 e PhE), atuando tanto no endotélio quanto diretamente em células do músculo liso vascular. O aumento da resposta a estímulos contráteis à ET-1 e PhE foi mediado pela via MEK-ERK1/2, COX-1 e COX-2 e aumento da expressão dos receptores para ET-1, ETA e ETB. Além disso, esta adipocina diminuiu a vasodilatação induzida pela ACh, por meio do desacoplamento da eNOS e aparente envolvimento de estresse oxidativo, e pelo NPS, através de ação sobre a guanilato ciclase. Nossos estudos poderão contribuir para um melhor entendimento sobre o papel dos fatores liberados pelo tecido adiposo visceral sobre a função vascular e, consequentemente, sobre as alterações vasculares presentes na obesidade e patologias associadas. / Although hypertrophy and hyperplasia of adipocytes as well as increased synthesis and release of adipokines are commonly observed in obesity, a condition associated with insulin resistance and endothelial dysfunction, it is extremely important to understand the biological effects of adipokines, or more specifically of the adipokine chemerin, in non-pathological conditions,. The mechanisms by which cytokines released by the adipose tissue may interfere with vascular function are not yet fully understood. Furthermore, the effects of the cytokine/adipokine chemerin on vascular function are not known. Considering that the chemerin receptor is expressed by vascular smooth muscle and endothelial cells, this study investigated the effects produced by this cytokine in vascular reactivity, as well as the mechanisms by which it modifies vascular function in non-obese animals. Our working hypothesis is that chemerin enhances vascular reactivity to constrictor stimuli, such as endothelin-1(ET-1) and phenylephrine (Phe), and decreases the vasodilation induced by acetylcholine (ACh) and sodium nitroprussiate (SNP). Our specific aims were to determine: 1) whether chemerin induces changes in vascular reactivity, 2) if the alterations of vascular reactivity induced by chemerin are mediated by changes in the function of endothelial cells or vascular smooth muscle cells, 3) which signaling pathways (focus on the MAPKs pathway) are being modified by chemerin and how they contribute to changes in vascular reactivity produced by this cytokine. Our study showed that the adipokine chemerin has biological and cellular activity in aortas from non-obese rats. Chemerin increased vascular responses to contractile stimuli (ET-1 and PhE), producing effects both in the endothelial and vascular smooth muscle cells. The increased contractile responses to ET-1 and PhE were mediated via activation of MEK-ERK1/2, COX-1 and COX-2 and increased expression of the ETA and ETB receptors. Furthermore, this adipokine reduced the vasodilation induced by ACh via eNOS uncoupling and oxidative stress, and by SNP, via effects in the enzyme guanylate cyclase. Our studies may contribute to a better understanding of the role of factors released by the visceral adipose tissue on vascular function and, consequently, on the vascular lesions in obesity and obesity-associated diseases.

A caquexia é um síndrome para neoplástica que interfere na morfologia e fisiologia do tecido adiposo. O objetivo do presente estudo foi avaliar os efeitos do treinamento de força e da suplementação de tributirina sobre os parâmetros da caquexia em animais inoculados com células do tumor de Walker 256. Ratos Wistar (n=7) foram randomizados em grupos experimentais: Controle (CT), Tumor (TB), Tumor tratado com tributirina (TBTrib), Treinado com Tumor (TFTB) e Tumor Treinado e suplementado com tributirina (TFTBTrib). Os parâmetros: peso tumoral, peso total carregado, quantidades de glicogênio, perfil plasmático, quantidades de citocinas, histologia do tecido adiposo foram analisados. Os grupos TBTrib e TFTBTrib tiveram menores quantidades de massa tumoral quando comparado com o grupo TB. O glicogênio muscular de TFTB e TFTBTrib estavam 37% e 35% maiores comparados com TB. As proteínas musculares aumentaram 48% e 50% para os grupos TFTB e TFTBTrib, sendo diferentes comparados com os grupos CT e TB. Se observou melhor balanço de IL-10/TNF-a nos grupos TFTB e TFTBTrib, sendo que a secção transversa diminuiu nos grupos TB e TBTrib. Se propõe que o treinamento de força e a suplementação de tributirina podem ser usados em trabalhos futuros com humanos. / Cachexia is a syndrome to neoplastic interfering in the morphology and physiology of adipose tissue. The aim of this study was to evaluate the effects of strength training and supplementation of tributyrin on the parameters of cachexia in animals inoculated with tumor cells of Walker 256 . Wistar rats (n = 7) were randomized into experimental groups : control (CT) , tumor (TB) , tumor treated with tributyrin (TBTrib) Trained with Tumor (TFTB) and Tumor Trained and supplemented with tributyrin (TFTBTrib). The parameters : tumor weight , total weight loaded amounts of glycogen , plasma levels , amounts of cytokines, histology of adipose tissue were analized. The TBTrib and TFTBTrib groups have smaller amounts of tumor mass compared to TB group. Muscle glycogen and TFTB TFTBTrib were 37% and 35% when compared to BD. The muscle proteins were 48% and 50%, respectively for TFTB and TFTBTrib groups being different when compared with TB and TC groups. Better balance was observed in groups IL-10/TNF-a TFTB and TFTBTrib , and the cross-section decreased in the groups TBTrib and TB. Proposes that resistance exercise and tributyrin supplementation can be used in future studies with humans.

Objetivo do estudo foi estudar a participação dos adipócitos e do fígado na inflamação e o papel da microbiota ao longo da progressão da caquexia. Para verificar o comportamento dos adipócitos e do fígado utilizamos ratos Wistar macho de 8 semanas, divididos em dois grupos: i) controle; ii) tumor. Este último foi subdividido em 2 grupos: a) 7º. e b) 14º. dia após a inoculação das células tumorais. Para avaliar o comportamento da microbiota durante o quadro de caquexia utilizamos camundongos C57Bl/6 convencional e germ free de 8-10 semanas, divididos em quatro grupos: i) Convencional controle; ii) Germ Free controle; iii) Convencional tumor; iv) Germ Free tumor. A célula tumoral usada para esse modelo foi Lewis Lung Carcinoma. Adipócitos isolados dos TAB, mesentérico, mais o fígado, mostraram que a via do inflamassoma esta ativa na fase terminal da caquexia. No modelo Germ Free, observamos que a caquexia apresenta-se é acelerada no tecido adiposo epididimal comparado aos camundongos convencionais tumor. Em conclusão, os adipócitos e o fígado desempenha papel importante no estabelecimento da inflamação, enquanto que a simbiose da microbiota parece ser essencial para combater a redução do tecido adiposo. / The goal of this study the role of adipocytes and liver inflammation and the role of microbiota along the progression of cachexia. The main aspects evaluated were increased of the inflammation, alteration in both pathways NF-kB and the inflammasome, and importance of the microbiota during progression of cachexia. To verify the behavior of adipocytes and liver I used Eight weeks-old male rats, I divided into two main groups: i) control; ii) tumor. The latter was divided into 2 groups: a) 7º. and b) 14º. day after tumor cell. To assess the microbial behavior during the development of cachexia I used C57BL/6 conventional mice and Germ Free 8-10 weeks, they were divided into four groups: i) Conventional control; ii) Germ Free control; iii) Conventional tumor; iv) Germ Free tumor. The tumor cell used in this model was Lewis Lung Carcinoma. Adipocytes isolated from TAB, mesenteric further the liver, showed that the inflammasome pathway is active in the terminal phase of cachexia. In model of Germ free mice we observed that cachexia is accelerated in epididymal adipose tissue compared to conventional tumor. In conclusion, adipocytes and liver seem to play a relevant role in the establishment of inflammation, while the microbial symbiosis seems to be essential for combating the reduction of adipose tissue.